Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Control BionicsASX:CBL -1.45% Debt-to-Equity is 0.03 as of Dec. 2025, which is 50% above its 10-year median of 0.02. The stock has 4 warning signs investors should review. Among 705 Medical Devices & Instruments companies, Control Bionics ranks better than 88.65% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Control Bionics's Debt-to-Equity or its related term are showing as below:
ASX:CBL'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.15
Current: 0.03
During the past 6 years, the highest Debt-to-Equity Ratio of Control Bionics was 0.15. The lowest was 0.00. And the median was 0.02.
ASX:CBL's Debt-to-Equity is ranked better than 88.65% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs ASX:CBL: 0.03
Control Bionics (ASX:CBL) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Control Bionics Debt-to-Equity Related Terms
Control Bionics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Control Bionics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CBL vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Control Bionics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Control Bionics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Control Bionics (ASX:CBL) has a Debt-to-Equity of 0.03 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Control Bionics and its competitors. This is 50% above median its historical median of 0.02. According to the industry distribution chart, Control Bionics ranks #80 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 11.3%.
Is Control Bionics' Debt-to-Equity too high?
Control Bionics' current Debt-to-Equity of 0.03 is 50% above median its 10-year median of 0.02. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Control Bionics' value of 0.03 is 87% below this industry median. Based on the distribution chart, Control Bionics ranks #80 out of 705 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Control Bionics' Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #80 out of 705 companies for Debt-to-Equity. This places Control Bionics in the top 11% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.23. Control Bionics' value of 0.03 is 87% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 0.23, Control Bionics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Control Bionics's current Debt-to-Equity of 0.03 is 87% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Control Bionics and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current Debt-to-Equity is 0.03, which is 50% above median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.07 — trading 126.7% above its estimated fair value. The current Debt-to-Equity is 0.03, which is 50% above median its 10-year median of 0.02 and 87% below the Medical Devices & Instruments industry median of 0.23. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current Debt-to-Equity is 0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your 
